Amgen Inc. made history on Oct. 27 by gaining the FDA's approval for the first oncolytic virus therapy – Imlygic (talimogene laherparepvec), which is indicated as a local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery.
Amgen Inc. made history on Oct. 27 by gaining the FDA's approval for the first oncolytic virus therapy – Imlygic (talimogene laherparepvec), which is indicated as a local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery.
Shares of Amgen got a 1.5% boost, or a gain of $2.52, in after-hours trading on Oct. 27.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
